Related Experiment Videos
Specific cell targeting for delivery of toxins into small-cell lung cancer using a streptavidin fusion protein
1Department of Medicine, New York University School of Medicine, and Chest Service, Bellevue Hospital Center, New York, USA.
Abstract:
New modalities of treatment for small-cell lung cancer (SCLC) are needed, because the majority of patients continue to die of disseminated disease despite an initial response to conventional chemotherapy. Abnormal surface expression of the neural-cell adhesion molecule (NCAM) has been noted to be highly associated with SCLC. We examined the ability and efficiency of a streptavidin-Protein A (ST-PA) fusion protein complexed with an anti-NCAM monoclonal antibody (Mab) to transfer biotinylated beta-galactosidase into human SCLC cell lines NCI-H69, NCI-H526, and NCI-H446. When the surface molecule NCAM was targeted with this system, more than 99% of the targeted cells internalized and exhibited beta-galactosidase activity. In addition, we evaluated cytotoxic activity against SCLC lines NCI-H69 and NCI-H526 by efficient delivery of biotinylated glucose oxidase using the same ST-PA/anti-NCAM Mab complex. Cytotoxicity of the transduced cells (SCLC) was 10-fold and 100-fold greater, respectively, than the glucose oxidase control. This system could be widely applied for specific therapy of cancer cells by targeting unique surface molecules (antigens) using the corresponding Mab/ST-PA complex to transfer a variety of effector molecules; e.g., immunotoxic compounds, into target cells with a high degree of efficiency and specificity.
Insights
Targeting neural-cell adhesion molecule (NCAM) on small-cell lung cancer (SCLC) cells with a novel streptavidin-Protein A/antibody complex efficiently delivered therapeutic payloads. This approach demonstrated high internalization rates and significant cancer cell cytotoxicity, offering a promising new SCLC treatment strategy.
Area of Science:
- Oncology
- Biotechnology
- Molecular Biology
Background:
- Small-cell lung cancer (SCLC) remains a significant challenge, with most patients succumbing to disseminated disease despite initial chemotherapy responses.
- Abnormal surface expression of neural-cell adhesion molecule (NCAM) is a hallmark of SCLC, presenting a potential therapeutic target.
Purpose of the Study:
- To evaluate a novel streptavidin-Protein A (ST-PA) fusion protein complexed with an anti-NCAM monoclonal antibody (Mab) for targeted delivery of effector molecules into SCLC cells.
- To assess the efficiency of this system in transferring beta-galactosidase and biotinylated glucose oxidase into human SCLC cell lines.
- To determine the cytotoxic activity of the targeted cells after delivery of glucose oxidase.
Main Methods:
- Utilized a streptavidin-Protein A (ST-PA) fusion protein complexed with an anti-NCAM monoclonal antibody (Mab).
- Targeted human SCLC cell lines (NCI-H69, NCI-H526, NCI-H446) expressing NCAM.
- Delivered biotinylated beta-galactosidase and biotinylated glucose oxidase into targeted cells.
Main Results:
- Achieved >99% internalization and beta-galactosidase activity in targeted SCLC cells.
- Demonstrated significant cytotoxic activity against SCLC cells upon delivery of biotinylated glucose oxidase, with 10-fold and 100-fold increases compared to controls.
- Validated the ST-PA/anti-NCAM Mab complex as an efficient delivery system for therapeutic payloads.
Conclusions:
- The ST-PA/anti-NCAM Mab complex provides a highly efficient and specific method for targeting SCLC cells.
- This system enables the targeted delivery of effector molecules, such as immunotoxic compounds, into cancer cells.
- This approach holds broad potential for developing targeted cancer therapies by leveraging unique surface antigens and corresponding antibody complexes.